Cambridge Investment Research Advisors
ORKA

Cambridge Investment Research Advisors’s Oruka Therapeutics ORKA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-48
Closed -$14K – 2239
2017
Q4 		$14K Hold
48
– – ﹤0.01% 2097
2017
Q3 		$12K Hold
48
– – ﹤0.01% 1991
2017
Q2 		$25K Hold
48
– – ﹤0.01% 1907
2017
Q1 		$27K Hold
48
– – ﹤0.01% 1748
2016
Q4 		$30K Hold
48
– – ﹤0.01% 1638
2016
Q3 		$30K Hold
48
– – ﹤0.01% 1715
2016
Q2 		$30K Buy
+48
New +$35.5K ﹤0.01% 1528

Other funds holding ORKA

TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACP
Aveo Capital Partners Englewood, Colorado $601M AUM 5.92% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Cambridge Investment Research Advisors's ORKA Position: Q1 2018 in Review

Cambridge Investment Research Advisors sold out of Oruka Therapeutics (ORKA) in Q1 2018, closing a stake of 48 shares — an estimated $14K sold.

Cambridge Investment Research Advisors first reported a position in ORKA in Q2 2016 and held it in 7 quarters. The position peaked at $30K in Q4 2016. 16 funds tracked by Wall St. Rank hold ORKA as of Q1 2018.

  • Cambridge Investment Research Advisors reported no remaining Oruka Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 48 Oruka Therapeutics shares in Q1 2018, an estimated $14K.
  • Cambridge Investment Research Advisors first reported a position in Oruka Therapeutics in Q2 2016 and held it in 7 quarters.
  • Cambridge Investment Research Advisors's Oruka Therapeutics position peaked at $30K in Q4 2016.
  • 16 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2018.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2018, filed 9 May 2018.